Bacillus subtilis B10

Bacillus subtilis B10 is a spore-forming probiotic bacterium that produces antimicrobial compounds and enzymes to support gut health. It enhances intestinal barrier function by increasing villus height and goblet cell production while modulating beneficial bacterial populations.

Origin & History

Bacillus subtilis B10 is a spore-forming, Gram-positive bacterial strain isolated for probiotic applications, particularly for modulating gut microbiota and improving growth performance in animals. As a clinical probiotic strain, it is cultured and prepared as viable spores or cells that demonstrate tolerance to low pH, bile salts, and ability to form biofilms and produce exoenzymes.

Historical & Cultural Context

No historical or traditional medicine use was identified for Bacillus subtilis B10 specifically, as it appears to be a modern research isolate. While general B. subtilis strains are found in fermented foods like nattō, the B10 strain has no documented traditional use.

Health Benefits

• Modulates gut microbiota composition by increasing beneficial bacteria like Streptococcus and altering Firmicutes/Bacteroidetes ratios (animal studies only)
• Enhances intestinal barrier function through improved villus height/width and increased goblet cells (demonstrated in broiler studies)
• Supports metabolic health by reducing weight gain, serum glucose, and hepatic triglycerides (shown in high-fat diet mouse models)
• Improves nutrient digestion through production of exoenzymes targeting proteins, lipids, and polysaccharides (mechanistic evidence from animal studies)
• Demonstrates pathogen exclusion potential through biofilm formation and adherence to intestinal matrix proteins (in vitro evidence)

How It Works

Bacillus subtilis B10 produces antimicrobial peptides like surfactin and iturin that inhibit pathogenic bacteria while promoting beneficial Streptococcus species. The strain enhances intestinal barrier integrity by stimulating goblet cell proliferation and mucin secretion. It modulates immune responses through toll-like receptor pathways and produces enzymes that aid nutrient digestion.

Scientific Research

Current evidence for Bacillus subtilis B10 is limited to animal studies, with no human clinical trials, RCTs, or meta-analyses identified. Key studies include a 72-day broiler feeding trial showing microbiota modulation and growth improvements at 1 × 10^8 CFU/kg feed, and mouse studies demonstrating metabolic benefits in high-fat diet-induced obesity models.

Clinical Summary

Current evidence for Bacillus subtilis B10 comes primarily from animal studies, particularly broiler chicken research. Studies have demonstrated improved villus height-to-width ratios and increased goblet cell density in intestinal tissue. Research shows modulation of gut microbiota with increased Firmicutes/Bacteroidetes ratios and enhanced Streptococcus populations. Human clinical trials specifically testing the B10 strain are currently limited, requiring more research to confirm benefits in humans.

Nutritional Profile

Bacillus subtilis B10 is a probiotic microorganism, not a conventional food ingredient, and thus does not contribute meaningful macronutrients or micronutrients in the quantities administered. Key bioactive contributions include: (1) Enzymatic secretions — B. subtilis strains are well-documented producers of proteases (subtilisin, neutral protease), amylases, lipases, and phytases, which enhance host digestion and nutrient bioavailability of feed/food components, particularly phosphorus liberation from phytate (phytase activity can increase phosphorus bioavailability by 20–40% in animal studies); (2) Antimicrobial peptides (bacteriocins) — produces lipopeptides including iturin A, surfactin, and fengycin, which contribute to competitive exclusion of pathogens rather than direct host nutrition; (3) Short-chain fatty acid (SCFA) stimulation — indirectly promotes butyrate, acetate, and propionate production in the colon through microbiota modulation, with butyrate concentrations in cecal contents reported to increase by approximately 15–30% in broiler studies; (4) Vitamin synthesis potential — B. subtilis species are known producers of riboflavin (vitamin B2) and menaquinone (vitamin K2, specifically MK-7), though strain-specific yield data for B10 designation is not independently published; (5) Protein/cell mass contribution — as a bacterial cell, B. subtilis contains approximately 50–60% protein (dry cell weight), ~15% nucleic acids, ~10% lipids, and ~10–15% carbohydrates (cell wall polysaccharides including teichoic acids), but these are present in negligible quantities at typical probiotic dosing levels (10^8–10^9 CFU/g); (6) Bioavailability note — the primary nutritional impact is indirect, mediated through enzymatic activity and microbiome modulation rather than direct nutrient delivery; spore-forming capacity of B. subtilis confers stability through processing and gastric transit, with spore survival rates reported above 85% after simulated gastric acid exposure (pH 2.0, 2 hours) in related B. subtilis strains.

Preparation & Dosage

Animal studies utilized 1 × 10^8 CFU/kg of feed for broilers over 72 days. No human dosages have been established for B10 specifically. General B. subtilis probiotics typically use spore forms at 10^8-10^9 CFU/day, but this is not B10-specific. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Other Bacillus strains, Lactobacillus species, prebiotic fibers, digestive enzymes, glutamine

Safety & Interactions

Bacillus subtilis B10 appears generally safe as a spore-forming probiotic with low risk of translocation due to its transient gut colonization. Potential side effects may include mild digestive upset during initial supplementation. No specific drug interactions have been reported, though antibiotic use may reduce effectiveness. Safety during pregnancy and lactation has not been established through human studies.